Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (21-30 of 137) with videos related to

Pageof 14
Sort By:
AIDS Research and Therapy|November 27, 2018
Ageing in patients with chronic HIV infection: impact of hypercoagulationStephen J Kent, Charles Flexner
Annual Review of Medicine|October 26, 2018
Long-Acting HIV Drugs for Treatment and PreventionRoy M Gulick, Charles Flexner
Current Opinion in HIV and AIDS|November 26, 2019
Long-acting implants to treat and prevent HIV infectionEthel D Weld, Charles Flexner
Annual Review of Pharmacology and Toxicology|November 13, 2012
Direct-acting antiviral agents for hepatitis C virus infectionJennifer J Kiser, Charles Flexner
Bioengineering & Translational Medicine|August 2, 2018
Harnessing nanostructured systems for improved treatment and prevention of HIV diseaseMaya Monroe, Charles Flexner, Honggang Cui
Nature Reviews. Drug Discovery|December 24, 2005
TipranavirCharles Flexner, Guy Bate, Peter Kirkpatrick
JAMA|January 7, 2026
Subscription-Based Pricing for Lenacapavir-Learning From Hepatitis C and CabotegravirMichael R Rose, Charles Flexner, Victor Roy
Current Opinion in HIV and AIDS|November 6, 2018
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitisCharles Flexner, David L Thomas, Susan Swindells
International Journal of Antimicrobial Agents|November 9, 2020
Long-acting drugs and formulations for the treatment and prevention of HIV infectionCharles Flexner, Andrew Owen, Marco Siccardi, et al.
The Lancet. Oncology|May 17, 2011
Use of antineoplastic agents in patients with cancer who have HIV/AIDSMichelle A Rudek, Charles Flexner, Richard F Ambinder
Pageof 14

Showing results (21-30 of 137) with videos related to

Sort By:
Pageof 14
AIDS Research and Therapy|November 27, 2018
Ageing in patients with chronic HIV infection: impact of hypercoagulationStephen J Kent, Charles Flexner
Annual Review of Medicine|October 26, 2018
Long-Acting HIV Drugs for Treatment and PreventionRoy M Gulick, Charles Flexner
Current Opinion in HIV and AIDS|November 26, 2019
Long-acting implants to treat and prevent HIV infectionEthel D Weld, Charles Flexner
Annual Review of Pharmacology and Toxicology|November 13, 2012
Direct-acting antiviral agents for hepatitis C virus infectionJennifer J Kiser, Charles Flexner
Bioengineering & Translational Medicine|August 2, 2018
Harnessing nanostructured systems for improved treatment and prevention of HIV diseaseMaya Monroe, Charles Flexner, Honggang Cui
Nature Reviews. Drug Discovery|December 24, 2005
TipranavirCharles Flexner, Guy Bate, Peter Kirkpatrick
JAMA|January 7, 2026
Subscription-Based Pricing for Lenacapavir-Learning From Hepatitis C and CabotegravirMichael R Rose, Charles Flexner, Victor Roy
Current Opinion in HIV and AIDS|November 6, 2018
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitisCharles Flexner, David L Thomas, Susan Swindells
International Journal of Antimicrobial Agents|November 9, 2020
Long-acting drugs and formulations for the treatment and prevention of HIV infectionCharles Flexner, Andrew Owen, Marco Siccardi, et al.
The Lancet. Oncology|May 17, 2011
Use of antineoplastic agents in patients with cancer who have HIV/AIDSMichelle A Rudek, Charles Flexner, Richard F Ambinder
Pageof 14